Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib

JAMA Dermatology

Volumn 151, Issue 1, 2015, Pages 102-103

  Lilly, Evelyn ^a   Burke, Matthew ^b   Kluger, Harriet ^b   Choi, Jennifer ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL; DABRAFENIB; LIDOCAINE; LONG ACTING DRUG; OXYCODONE; PREGABALIN; TAZAROTENE; UREA; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR;

ADL DISABILITY; ADULT; ANALGESIA; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FOOT SOLE; HAND FOOT SYNDROME; HAND PALM; HUMAN; LOW DRUG DOSE; MALE; MEDICAL HISTORY; METACARPOPHALANGEAL JOINT; METASTATIC MELANOMA; OINTMENT; OUTCOME ASSESSMENT; PAIN; SKIN EXAMINATION; SKIN MANIFESTATION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; HAND-FOOT SYNDROME; MIDDLE AGED; TREATMENT OUTCOME;

ANALGESICS; ANTINEOPLASTIC AGENTS; GAMMA-AMINOBUTYRIC ACID; HAND-FOOT SYNDROME; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; TREATMENT OUTCOME;

EID: 84921328571     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.2455     Document Type: Article

References (5)

1. Lacouture ME, Duvic M, Hauschild A, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18(3):314-322.
2. Belum VR, Fischer A, Choi JN, Lacouture ME. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep. 2013;15(3):249-259.
3. Choi JN. Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts. Clin Dermatol. 2011;29(6):587-601.
4. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691-1697.
5. Freynhagen R, Serpell M, Emir B, et al. A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract. 2013; doi:10.1111/papr.12146.